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ZIKA, PREGNANCY, AND THE LAW 
Sam F. Halabi∗ 
I.  INTRODUCTION 
The public health emergency surrounding the spread of the 
Zika virus has resurrected and brought into sharp relief some of 
the most vexing questions surrounding the relationship between 
pregnancy and law: the appropriate circumstances, if any, in 
which fetal tissue research is permissible;1 when and how the 
government may sponsor statements intended to influence 
reproductive decisions;2 and how to balance the health and rights 
of both women and their unborn children when health threats 
target both.3  This latter question has come to the forefront in the 
       ∗ Associate Professor, University of Missouri School of Law and Scholar, O’Neill 
Institute for National and Global Health Law, Georgetown University; J.D., Harvard Law 
School; M.Phil., University of Oxford; B.S., Kansas State University.  The author is grateful 
for comments given at the Loyola University-Chicago Conference on Innovations and 
Incentives in Life Sciences as well as the American Society for Law, Medicine, and Ethics 
Health Professor Conference. 
1. Erika Check Hayden, Zika Highlights Role of Fetal-Tissue Research, 532 NATURE
16, 16 (2016), https://www.nature.com /polopoly_fs /1.19655! /menu /main / topColumns 
/topLeftColumn/pdf/nature.2016.19655.pdf [https://perma.cc/J5RM-Q2DH]; Doug 
Wassenaar, Ethics Considerations in Zika Vaccine Research: An Approach, WORLD 
HEALTH ORG. (June 7, 2016),  http://www.who.int /  immunization /research 
/meetings_workshops /2_Douglas_Wassenaar_zika_june_16.pdf [https://perma.cc/7NH4-
8LLJ]; Julie Steenhuysen, Researchers Find New Zika Clues to Birth Defect in Fetus Study, 
REUTERS, Feb. 10, 2016, http://www.reuters.com /article /us-health-zika-science-
idUSKCN0VJ2M7 [https://perma.cc/R47W-XM2Y]. 
2.  RUTH MACKLIN, ETHICS IN GLOBAL HEALTH: RESEARCH, POLICY, AND PRACTICE
50 (2012) (noting influence of governments in shaping reproductive decisions); see generally 
Zika: How to Communicate Effectively, CTRS. FOR DISEASE CONTROL & PREVENTION: 
ZIKA ACTION PLAN SUMMIT (Apr. 2016), https://www.cdc.gov/zap/pdfs/presentations/zap-
communicate-effectively.pdf [https://perma.cc/EAN5-USRS]; Robert P.S. Jansen, 
Evidence-Based Ethics and Regulation of Reproduction, 12 HUM. REPROD. 2068 (1997), 
https://doi.org/ 10.1093/humrep/12.9.2068 [https://perma.cc/H5Y2-56MZ] (detailing 
historical ethical difficulties between government sponsorship and reproductive choice). 
3. AM. COLL. OF OBSTETRICIANS & GYNECOLOGISTS, COMM. OP. NO. 563, ETHICAL 
ISSUES IN PANDEMIC INFLUENZA PLANNING CONCERNING PREGNANT WOMEN 1-2 (2013, 
reaff’d 2016), https://www.acog.org/Resources-And-Publications/ Committee-
Opinions/Committee-on-Ethics/Ethical-Issues-in-Pandemic-Influenza-Planning-
Concerning-Pregnant-Women [https://perma.cc/VT7H-8L38]. 
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Zika context.  Because the virus inflicts its heaviest known toll in 
utero, research undertaken for treatments or vaccines will 
inevitably implicate application of that research to pregnant 
women.4 
Yet the Zika public health emergency also arises at a time in 
which legal scholars have recently launched a reevaluation, 
reexamination, and reimagination of the relationship between 
pregnancy and law across a number of fields including criminal 
law, disability law, poverty law, and employment discrimination, 
among others.  Broadly speaking, these scholars assert that 
legislatures, courts, and regulators have “essentialized” 
pregnancy—reducing it to factors specific to gestation—in ways 
that undermine pregnant women’s rights to work,5 disrespect or 
unequally burden their autonomy under statutory regimes 
informed and shaped by Roe v. Wade,6 and arbitrarily subject 
pregnant women to penal statutes in both the civil and criminal 
contexts.7  The debate under way is not limited to the academy: 
both Hillary Clinton and Donald Trump campaigned in part on 
4. See generally Jon Cohen, The Race for a Zika Vaccine is On, 351 SCIENCE 543
(2016), http://science.sciencemag.org/content/351/6273/543 [https://perma.cc/ 3945-
TBMJ]. 
5. Deborah A. Widiss, Gilbert Redux: The Interaction of the Pregnancy
Discrimination Act and the Amended Americans with Disabilities Act, 46 U.C. DAVIS L. 
REV. 961, 1002 (2013) (“Courts have also failed to develop the robust understanding of 
“‘equal opportunity’—that is, the right of ‘women, as well as men, to have families without 
losing their jobs’—endorsed in Cal Fed as a justification for providing pregnancy-specific 
benefits.”).  
6. Michele Goodwin, Prosecuting the Womb, 76 GEO. WASH. L. REV. 1657, 1663
(2008) (“In fact, FDLs [fetal drug laws] do little to tell us about harms to fetuses as these 
laws exempt from prosecution a host of behaviors that negatively impact pregnancies and 
cause miscarriages, such as smoking, second-hand smoke, diabetes, obesity, depression, and 
hypertension.  Indeed, a good number of FDLs have exemptions for legal abortions so that 
they may remain consistent with Roe v. Wade.”). 
7. Doretta Massardo McGinnis, Prosecution of Mothers of Drug-Exposed Babies:
Constitutional and Criminal Theory, 139 U. PENN. L. REV. 505, 511-13 (1990); see generally 
Barry M Lester, Lynne Andreozzi, & Lindsey Appiah, Substance Use During Pregnancy: 
Time for Policy to Catch Up with Research, 1 HARM REDUCTION J. 5 (2004), 
https://doi.org/10.1186/1477-7517-1-5 [https:// perma.cc/8JFK-QYE3] (“We have Supreme 
Court rulings that define drug use as a mental problem, we have modern evidence that 
treatment is effective and that there is no reason to consider drug use as different than any 
other mental/medical problem; there are treatment programs shown to be effective with drug-
using mothers; and there are treatments with the programs involving the courts. We have 
identified all other barriers, yet why has policy not changed? Is it because we are still angry 
and want to punish these mothers? That we will not forgive them for using drugs when they 
are pregnant?”).  
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expanding support for new mothers, implicitly acknowledging 
the social and medical importance of the “fourth trimester.”8 
According to the essentialist argument, pregnancy is 
reduced, under the law, to “biological and physiological facets, 
obscuring the important ways in which society and culture shape 
the meaning of pregnancy and structure our experience of it.”9  
Equality-promotion statutes like the Pregnancy Discrimination 
Act and the Family Medical Leave Act (FMLA) codify this 
essentialism.10  These statutes impose specific burdens that are 
measured and implemented, such as accommodations employers 
must provide for pregnant employees or appropriate windows for 
family medical leave, whatever the additional costs pregnancy 
might impose on a woman, her co-parents or caregivers (if any), 
and/or family.11  As a result, new mothers are left to shoulder a 
burden related to reproduction heavier than that for men.12  To the 
extent these scholars have explored the relationship between 
medical decisions made by pregnant women, they have done so 
largely around issues like reproductive choice, the constraints of 
the “code of perfect pregnancy,” and the disparate treatment the 
law accords specific decisions made by women during 
pregnancy.13  The process by which medical information is 
generated, filtered, and ultimately communicated to pregnant 
women has received far less scrutiny.14 
8. Jill Cohen, The Fourth Trimester, 61 MIDWIFERY TODAY 26 (2002); Melinda
Wenner Moyer, If Trump Keeps His Promise on Paid Family Leave, Will Working Women 
Feel They Can Take It?, SCI. AM. (Jan. 20, 2017), https:// www.  scientificamerican.com 
/article/if-trump-keeps-his-promise-on-paid-family-leave-will-working-women-feel-they-
can-take-it/ [https://perma.cc/Y3BR-SH5L]; Megan A. Sholar, Donald Trump and Hillary 
Clinton Both Support Paid Family Leave. That’s a Breakthrough., WASH. POST (Sept. 22, 
2016), https://www.washingtonpost.com/ news/ monkey-cage/ wp/ 2016/ 09/ 22/ donald-
trump-and-hillary-clinton-both-support-paid-family-leave-thats-a-breakthrough/ ?utm_term 
=.baff3914546c [https://perma.cc/ S272-BH8G].  
9. Saru M. Matambanadzo, Reconstructing Pregnancy, 69 SMU L. REV. 187, 190
(2016).  
10. Deborah Dinner, The Costs of Reproduction: History and the Legal Construction
of Sex Equality, 46 HARV. C.R.-C.L. L. REV. 415, 422 (2011) (“The PDA and the FMLA 
both prohibit sex-role stereotyping and impose cost-sharing mandates on employers.”). 
11. Id.
12. Id.
13.  See generally Lisa C. Ikemoto, The Code of Perfect Pregnancy:  At the Intersection 
of the Ideology of Motherhood, the Practice of Defaulting to Science, and the Interventionist 
Mindset of Law, 53 OHIO ST. L.J. 1205 (1992). 
14.  It is worth noting here that this article is limited to legislative and regulatory efforts 
aimed at pregnancy as an intended condition.  An entirely separate conversation is relevant 
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This Essay situates a crucial component of the public health 
response to Zika—the effort to develop a safe and effective 
vaccine—within this broader literature.  It does so in an effort to 
highlight the need to revisit the relationship between law and 
pregnancy—not only in the areas legal scholars have prioritized 
so far, but also in the context of routine and emergency maternal 
health, which has heretofore been largely assumed to be governed 
by straightforward norms and practices based on medical 
evidence and physician ethics.15  In fact, whereas the current 
literature tends to assume or explicitly assert that the relationship 
between law and pregnancy is most troubled in the contexts of 
reproductive choice, the workplace, or criminal prosecution—i.e. 
predictable events and moments that may be assessed at any given 
time—it has paid far less attention to emergency contexts like 
H1N1, Ebola, or Zika, each of which uniquely affects or affected 
pregnant women.16  In so doing, the literature suggests that social 
constructions regulating pregnancy in the workplace or the 
prosecutor’s office also regulate the deliberations of public health 
officials, physicians, and the medical advice communicated from 
them. 
Examining the approach adopted by health and medical 
regulatory authorities in the U.S. (and mimicked by competent 
national regulatory authorities elsewhere) toward pregnant 
women in public health emergencies, this Essay argues that 
medical research and therapeutic availability are structured so as 
to minimize accessibility to pregnant women, even where 
evidence suggests—as it did with Ebola and does with Zika—that 
to legislative efforts to filter and shape medical information so as to deter abortion.  See, e.g., 
Sandhya Somashekhar, Ohio Governor Vetoes ‘Heartbeat Bill’ But Signs Another Abortion 
Restriction into Law, WASH. POST., Dec. 13, 2016, https://www.washingtonpost.com 
/news/post-nation/wp/ 2016/12/13/ohio-governor-vetoes-heartbeat-bill-but-signs-into-law-
another-abortion-restriction/?utm_term=.3939ee570b8a [https://perma.cc/TPC5-HTQX]. 
15. Margaret Olivia Little et al., Ethics and Research with Pregnant Women: Lessons
from HIV/AIDS, in 3 CLINICAL RESEARCH INVOLVING PREGNANT WOMEN 227, 237-39 
(2016). 
16. Kate Greenwood, The Mysteries of Pregnancy: The Role of Law in Solving the
Problem of Unknown But Knowable Maternal-Fetal Medication Risk, 79 U. CIN. L. REV. 
267, 268 (2011) (identifying unique risks H1N1 posed to pregnant women); see generally 
Annick Antierens, Ethical Challenges in the Development and Deployment of Medical 
Therapies and Vaccines in the Context of Public Health Emergencies, in GLOBAL 
MANAGEMENT OF INFECTIOUS DISEASE AFTER EBOLA 207, 215 (Sam F. Halabi, Lawrence 
O. Gostin & Jeffrey S. Crowley eds., 2017) [hereinafter GLOBAL MANAGEMENT] 
(identifying unique risks Ebola posed to pregnant women and their fetuses). 
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accessibility for pregnant women needs to be prioritized.  Under 
this approach, the U.S. Food and Drug Administration (FDA), 
which normally must approve medicines and vaccines intended 
for specific populations, effectively allocates maternal treatment 
and immunization regulation to the Centers for Disease Control 
and Prevention (CDC)’ Advisory Committee on Immunization 
Practices, the World Health Organization’s strategic advisory 
group of experts on immunization, and other national 
immunization technical advisory groups.17  Where those 
organizations recommend immunization of pregnant women, the 
FDA does not consider the use inconsistent with the product’s 
authorized uses or “off-label,” even if there are never double-
blind, placebo controlled trials supporting safety and efficacy 
(regardless of whether there are healthy and willing volunteers)—
and trials are rarely designed that seek pregnant participants.18 
While this Essay has as its principal aim the expansion and 
catalysis of an important element of the debate now underway in 
the law, it also outlines the adverse consequences resulting from 
the existing regulatory framework for pregnancy-specific 
vaccines (“maternal vaccines”) and foreshadows changes that 
will not only be necessary to address future public health 
emergencies that threaten pregnant women and their unborn 
children, but will also unlock the future of vaccine preventable 
deaths.19  As the world moves toward universal coverage of 
17. Richard H. Beigi et al., Research on Vaccines and Antimicrobials During
Pregnancy: Challenges and Opportunities, 31 VACCINE 4261, 4261—63 (2013), 
http://www.sciencedirect.com /science /article /pii/ S0264410X13006622 [https://perma 
.cc/S5G3-9ZLK]. 
18. Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831,
30,840–41 (proposed May 29, 2008) (to be codified at 21 C.F.R. pt. 201) (“Therefore, human 
data concerning a drug’s effect(s) on pregnant women and their offspring almost never come 
from controlled clinical trials. . . . Sources that may contribute to an evaluation of whether a 
drug increases the risk of developmental abnormalities include pregnancy exposure 
registries, cohort studies, case-control studies, case series, and case reports.”); Jeffery N. 
Roberts & Marion F. Gruber, Regulatory Considerations in the Clinical Development of 
Vaccines Indicated for Use During Pregnancy, 33 VACCINE 966, 967 (2015), 
http://www.sciencedirect.com/ science/ article/ pii/S0264410X1401723X  
[https://perma.cc/FSK3-SPZ7].  
19.  A “maternal” vaccine may designate an immunization administered before, during,
or after pregnancy and the use is not consistent in the literature.  See generally Stanley A. 
Gall, A Maternal Immunization Program (MIP): Developing a Schedule and Platform for 
Routine Immunization During Pregnancy, 29 VACCINE 9411, 9411—13 (2011), 
http://www.sciencedirect.com /science /article /pii /S0264410X 11017634 
[https://perma.cc/G3SC-ZM45].  In this Essay, a “maternal” vaccine refers to one 
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childhood immunizations, the future of infant health will turn to 
immunizations delivered during pregnancy that impart 
protections unavailable after birth.20  This Essay encourages a 
new national and international dialogue about maternal and infant 
health, and addresses the norms that now characterize biomedical 
innovation and corresponding regulatory approaches to 
pregnancy. 
Part II of this Essay analyzes the recent trend among scholars 
to characterize the “essentialist” view of pregnancy legal regimes, 
ranging from criminal law to workplace discrimination, adoption, 
and the effects of essentialism on women generally and pregnant 
women specifically.  It then demonstrates that this scholarship has 
tended to explicitly assert or implicitly suggest that there is 
nevertheless a zone, occurring within the provider-patient 
relationship, where the law is less distorted and medical evidence 
and physician good faith prevail, even if imperfectly so.  Part III 
tests this assumption in the literature by analyzing the regulatory 
complexities surrounding the licensing of vaccines intended for 
pregnancy—including why pregnant women are excluded from 
clinical trials, the relationship between product labeling and 
vaccine hesitancy among pregnant women, and recent statutory 
and regulatory changes aimed at facilitating pregnant women’s 
access to essential medicines and vaccines.  It concludes that the 
administered or intended to be administered to a woman known to be pregnant between 
conception and the end of the pregnancy.  See, e.g., Maternal Vaccines: Part of a Healthy 
Pregnancy, CTRS. FOR DISEASE CONTROL & PREVENTION (Aug. 5, 2016), 
https://www.cdc.gov/vaccines/pregnancy/pregnant-women/ [https://perma.cc/474L-HDL9]. 
20. WORLD HEALTH ORG. ET AL., STATE OF THE WORLD’S VACCINES AND
IMMUNIZATION 75 (3d ed. 2009), http://apps.who.int/iris/bitstream/10665/44169/ 
1/9789241563864_eng.pdf [https://perma.cc/Q7B7-ZM8G] (“First came the vaccines: by 
the early 1970s, vaccines against about 20 diseases had become available, and in most 
countries were being used for high-risk population groups (travellers, the military, and so 
on), or for occasional mass campaigns, but not routinely in a systematic organized manner. 
Then, starting in the mid-1970s, came the [WHO Expanded Programme on Immunization]—
set up to establish and coordinate, on a global scale, the systematic use of vaccines by 
national immunization programmes and thereby to protect as many children as possible in 
the world against six infectious diseases (diphtheria, tetanus, pertussis, measles, polio, and 
tuberculosis). In the mid-1980s, came the evidence that these immunization programmes 
could, in a matter of a few years, protect millions of children from disease and death.  By the 
early 1990s, the drive for universal child immunization (UCI) launched by UNICEF, WHO, 
and other partners, had helped raise immunization coverage to a global average of about 
80%.”); Seth Berkley, Global Vaccine Access as a Critical Intervention to Fight Infectious 
Disease, Antibiotic Resistance, and Poverty, in GLOBAL MANAGEMENT, supra note 16, at 
179, 179-81 (noting progress toward universal childhood immunization). 
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essentialist approach identified in other legal fields is applicable 
to maternal immunizations in both the routine and emergency 
contexts; that, as a result, pregnant women’s access to lifesaving 
vaccines is thwarted, and development of ethical approaches to 
pregnancy-related research is stymied; and that, as with other 
legal fields, pregnant women are ultimately disadvantaged 
relative to other populations. 
II. PREGNANCY AND THE LAW: A REEVALUATION
As the 40th anniversary of the Pregnancy Discrimination Act 
and the 25th anniversary of the Family Medical Leave Act 
approach (as well as the 30th anniversary of the largest expansion 
of prenatal care to low-income pregnant women through 
Medicaid),21 legal scholars have undertaken a comprehensive 
review of multiple legal regimes aimed at promoting equality 
between pregnant women and other workers, criticizing aspects 
of the law that unfairly subject pregnant women to prosecution,22 
and evaluating laws aimed at supporting pregnancy.23 
Contemporaneously, a growing body of medical and public health 
literature suggests the benefits of providing better financial and 
other forms of support to women after the birth of children, in 
addition to the long-known benefits of prenatal care.24  The issue 
21. Marilyn Rymer Ellwood & Genevieve Kenney, Medicaid and Pregnant Women:
Who is Being Enrolled and When, HEALTH CARE FIN. REV., Winter 1995, at 7 (“During the 
late 1980s, Congress focused heavily on expanding Medicaid eligibility at the State level for 
low-income pregnant women.”).   
22. Deborah L. Brake & Joanna L. Grossman, Unprotected Sex: The Pregnancy
Discrimination Act at 35, 20 DUKE J. GENDER L. & POL’Y 67, 67-68 (2013); Saru 
Matambanadzo, The Fourth Trimester, 48 U. MICH. J.L. REFORM 117, 121 (2014), 
http://repository.law.umich.edu/ cgi/ viewcontent.cgi? article= 1121&context=mjlr 
[https://perma.cc/9DX4-SVUV] (reviewing this scholarly undertaking). 
23. Candace Marie Reder, Framing Preglimony: Exploring the Implications of
Pregnancy Support Models Through Family Law Values, 20 DUKE J. GENDER L. & POL’Y 
325, 327 (2013) (analyzing historical trends in American law supporting pregnancy and 
concluding that “the eventual implementation of a pregnancy support scheme seem[s] 
inevitable”).   
24.  See generally Greg R. Alexander et al., Source of Bias in Prenatal Care Utilization 
Indices: Implications for Evaluating the Medicaid Expansion, 81 AM. J. PUB. HEALTH 1013 
(1991), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1405696/ [https://perma.cc/N7UY-
99HK]; Pinka Chatterji & Sara Markowitz, Family Leave After Childbirth and the Mental 
Health of New Mothers, 15 J. MENTAL HEALTH POL’Y & ECON. 61 (2012), 
http://www.icmpe.org/test1/docs/15-061_text.pdf [https://perma.cc/2VEK-N9UL]; Ann 
D. Colle & Michael Grossman, Determinants of Pediatric Care Utilization, 13 J. HUM. RES. 
115 (1978), http://www.nber.org/ papers/w0240.pdf [https://perma.cc/J9HB-F8QN]; Mark 
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of better laws for pregnant women became a rare point of 
agreement between the two major presidential candidates in the 
2016 U.S. elections.25 
At the core of this effort is the promotion of a more 
comprehensive view of pregnancy, of the costs it imposes, and 
how those costs are distributed over a society that, generally, aims 
to promote not only equality between men and women but healthy 
generations to succeed them.26  The law, according to these 
scholars, takes an “essentialist” view of pregnancy, 
conceptualizing it “for much of gestation as an individual process 
that need not involve partners or other family members. 
Pregnancy is individual for the majority of [its] duration” because 
of a social choice to make it so.27  This process is fundamentally 
biological and medical: it involves mainly gestation and perhaps 
gastrointestinal symptoms, fluctuation in blood pressure, chronic 
pain, nausea, changes in body size, and distribution of body 
mass.28  That it involves a great deal more is, effectively, ignored, 
at least insofar as the law is concerned.29 
Daku, Amy Raub & Jody Heymann, Maternal Leave Policies and Vaccination Coverage: A 
Global Analysis, 74 SOC. SCI. & MED. 120 (2012), http:// www. sciencedirect.com/ science/ 
article/ pii/ S0277953611006563 [https://perma.cc/HV59-BHQ4]; Mary Kathryn Hamman, 
Making Time for Well-Baby Care: The Role of Maternal Employment, 15 MATERNAL & 
CHILD HEALTH J. 1029  (2011), https://link.springer.com/article/ 10.1007/s10995-010-0657-
9 [https://perma.cc/8KG6-Q9ZF]; R.S. McDuffie, Jr. et al., Effect of Frequency of Prenatal 
Care Visits on Perinatal Outcome Among Low-Risk Women: A Randomized Controlled 
Trial, 275 JAMA 847 (1996); Pat McGovern et al., Postpartum Health of Employed Mothers 
5 Weeks After Childbirth, 4 ANNALS FAM. MED. 159 (2006), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1467019/ pdf/0040159.pdf 
[https://perma.cc/Y557-5HFL]; Claire Cain Miller, The Economic Benefits of Paid Parental 
Leave, N.Y. TIMES (Jan. 30, 2015), https://www.nytimes .com/2015/02/01/upshot/the-
economic-benefits-of-paid-parental-leave.html?_r=0 [https://perma.cc/6755-UDXL]. 
25. Paid Family and Medical Leave, HILLARY FOR AM., https:// www. hillaryclinton 
.com/ issues /paid-leave / [https://perma.cc/BTS8-9ZNP] (“As president, Hillary will: 
Guarantee [sic] up to 12 weeks of paid family and medical leave to care for a new child or a 
seriously ill family member, and up to 12 weeks of medical leave to recover from a serious 
illness or injury of their own.”); Richard Pérez-Peña, How the Trump and Clinton Child Care 
Plans Stack Up, N.Y. TIMES (Sept. 14, 2016), https://nyti.ms/2cPbody 
[https://perma.cc/8X9S-RE82 ] (“[Trump] proposed requiring employers to give six weeks 
of maternity leave . . . .”).   
26. Muller v. Oregon, 208 U.S. 412, 421 (1908).
27. See Matambanadzo, supra note 9, at 252.
28. Id. at 256.
29. See Matambanadzo, supra note 22, at 129; see also Erma Jean Lawson & Shireen
Rajaram, A Transformed Pregnancy: The Psychosocial Consequences of Gestational 
Diabetes, 16 SOC. HEALTH & ILLNESS 536, 537 (1994) (“Researchers have focused 
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This essentialism distorts laws aimed at promoting equality 
for pregnant women, subjects them to arbitrary legal 
disadvantages, and unfairly distributes the costs of reproduction 
over all of the social actors who benefit from healthy mothers and 
babies.30  In the context of pregnancy discrimination, Saru 
Matambanadzo has argued that this essentialism explains why 
Congress has failed to pass legislation extending discrimination 
protection to reproductive choice, breastfeeding, fertility 
treatments, or even infant care.31  Even within the primary 
antidiscrimination statute meant to protect pregnant women—the 
Pregnancy Discrimination Act—“many courts currently reduce 
pregnancy discrimination to gestation-based discrimination, 
obscuring not only social and cultural aspects of pregnancy 
discrimination, but also a host of medical conditions that are 
explicitly related to pregnancy and childbirth . . . .”32  Deborah 
Dinner has persuasively argued that the “design of workplace 
structures” has incorporated this essentialism “in a manner that 
disproportionately burdens women” so as to conserve an obsolete 
model of family-wage earning under which men are breadwinners 
and women are caregivers.33 
While the Pregnancy Discrimination Act was intended to 
level the playing field between pregnant and non-pregnant 
workers,34 the Family Medical Leave Act (though phrased in sex-
considerable attention on the psychological transitions of a ‘normal’ pregnancy. Sociological 
models have reported that the medicalisation of reproduction, the social subordination of 
women, and the social construction of motherhood influence the psychological 
disequilibrium of pregnancy”); see generally Claudia Barcellos Rezende, The Experience of 
Pregnancy: Subjectivity and Social Relations, 8 VIBRANT: BRAZ. J. ANTHROPOLOGY 529 
(2011), http://www.scielo.br/ scielo.php? script=sci_arttext&pid=S1809-
43412011000200026 [https://perma.cc/4ZJE -29DF]. 
30. The year 2018 is also the 30th anniversary of the effective date of the substantial
Medicaid expansion for pregnant women under the federal Omnibus Budget Reconciliation 
Act.  States rapidly adopted expansions for low-income pregnant women under the law. 
Deborah A. Calloway, Accommodating Pregnancy in the Workplace, 25 STETSON L. REV. 
1, 19-21 (1995) (detailing adverse social outcomes from not supporting pregnant women); 
Ian T. Hill, Improving State Medicaid Programs for Pregnant Women and Children, 
HEALTHCARE FIN. REV., Dec. 1990, at 76. 
31. See Matambanadzo, supra note 9, at 257.
32. Id. at 259; see generally Widiss, supra note 5.
33. See Dinner, supra note 10, at 487.
34. Pregnancy Discrimination Act of 1978, 42 U.S.C. § 2000e(k) (2006); Joanna L.
Grossman, Pregnancy, Work, and the Promise of Equal Citizenship, 98 GEO. L.J. 567, 602-
05 (2010); Joanna L. Grossman, Hard Labor: New Pregnancy Discrimination Guidance 
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neutral language), was aimed at protecting women generally and 
pregnant women specifically.35  The FMLA allows women to 
take “serious health condition” leave for needed prenatal care or 
if the pregnancy causes inability to work, or as needed for 
childbirth, recovery, and to care for a newborn child.36  Because 
of the FMLA’s notice requirements, limited benefits, and total 12-
week protection from adverse employment consequences, it has 
had a modest impact in improving outcomes for women and 
children.37  The essentialist critique explains, in part, this limited 
effect.  Because the entire statutory leave is 12 weeks, women 
who must take leave for gestation-related conditions lose time 
that may be taken after birth.38 
This essentialism not only shapes and distorts law ostensibly 
aimed at protecting pregnant women from discrimination, but 
results in the drafting of criminal statutes that selectively favor 
some conduct during pregnancy but not other conduct that might 
be just as harmful to a pregnant woman or her fetus.  Michele 
Goodwin, for example, argues that fetal drug laws, which subject 
women to prosecution for conduct that harms a fetus, substitute 
medical evidence as to fetal harm with notions of “birthing the 
right way” based on conceptions related to essentialist ideas.39  
from the EEOC, VERDICT (July 22, 2014), http://scholarlycommons.law.hofstra.edu/ 
faculty_scholarship/355 [https://perma.cc/9YSY-5YXE]. 
35. 29 U.S.C. § 2601 (2012); Joanna L. Grossman & Gillian L. Thomas, Making
Pregnancy Work: Overcoming the Pregnancy Discrimination Act’s Capacity-Based Model, 
21 YALE J.L. & FEMINISM 15, 25 (2009). 
36. 29 U.S.C. § 2612(a) (2012).
37. Rafael Gely & Timothy D. Chandler, Maternity Leave Under the FMLA: An
Analysis of the Litigation Experience, 15 WASH. U. J.L. & POL’Y 143, 151 (2004) 
(“However, the data also suggests that the impact has been rather modest, particularly with 
regard to employees that need to take leave due to birth or adoption.”); Michael Selmi, The 
Limited Vision of the Family and Medical Leave Act, 44 VILL. L. REV. 395, 396 (1999) 
(arguing that “the FMLA was primarily a symbolic act, which afforded no significant 
assistance to working women, or men, and has perhaps retarded progress on the family leave 
front more than it has plausibly helped”); see generally Richard Bales & Sarah Nefzger, 
Employer Notice Requirements Under the Family and Medical Leave Act, 67 MO. L. REV. 
883 (2002) (discussing notice provisions). 
38. Lawrence M. Berger, Jennifer Hill & Jane Waldfogel, Maternity Leave, Early
Maternal Employment and Child Health and Development in the US, ECON. J., Feb. 2005, at 
F31-32. 
39. Michele Goodwin, Fetal Protection Laws: Moral Panic and the New
Constitutional Battlefront, 102 CAL. L. REV. 781, 786 (2014) (“[L]egislative fetal protection 
efforts are on the rise, driving the creation, enactment, and enforcement of statutes 
authorizing criminal intervention in women’s pregnancies. These statutes dramatically 
exceed prior limits, extending beyond penalizing poor African American pregnant women 
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For pregnant women in prison, medical care and alternatives to 
prison routines are similarly structured around gestation-focused 
conceptions of how women experience pregnancy.40 
Yet, for the reach and strength of these arguments 
challenging the legal environment for pregnant women, the zone 
that surrounds the public health approach to pregnant women 
generally and the physician-patient relationship specifically has 
received far less scrutiny from legal scholars.  So, for example, 
Professor Matambanadzo contrasts federal judges’ knowledge 
(and the resulting narrowing interpretation of the Pregnancy 
Discrimination Act) with the “sophisticated medical and 
scientific knowledge that many doctors, maternal nurses, and 
midwives possess.”41  Deborah Widiss identifies dozens of 
Pregnancy Discrimination Act cases in which women requested 
accommodations under doctors’ orders and how courts failed to 
give the physician-patient relationship the deference it 
deserved.42  Even within the quite large literature on “maternal-
fetal” conflict, which as Michelle Oberman points out, may be 
rearticulated as a “maternal-physician” conflict, the arguments 
largely revolve around points where evidence and advice 
diverge—like cesarean births—as opposed to routine maternal 
care or recommendations made in the course of public health 
emergencies.43 
for illicit drug use, particularly crystallized cocaine (crack). Contemporary fetal 
protectionism includes sanctioning women for refusing cesarean sections, forcibly confining 
them to bed rest, and instigating prosecutions for otherwise legal conduct.”); Goodwin, supra 
note 6, at 1661-62. 
40. Deborah Ahrens, Incarcerated Childbirth and Broader “Birth Control”:
Autonomy, Regulation, and the State, 80 MO. L. REV. 1, 4 (2015) (“In the past decade, there 
have been a number of academic articles and interest-group reports that document the 
problems that women who are pregnant and birthing face while incarcerated, and those 
articles and reports have focused in particular on the practice of shackling women who are 
pregnant during transportation, court appearances, and, most sympathetically, labor.”); 
Pricilla A. Ocen, Punishing Pregnancy: Race, Incarceration, and the Shackling of Pregnant 
Prisoners, 100 CAL. L. REV. 1239, 1310 (2012); Kelly Parker, Pregnant Women Inmates: 
Evaluating Their Rights and Identifying Opportunities for Improvements in Their Treatment, 
19 J.L. & HEALTH 259, 261-64 (2004). 
41. See Matambanadzo, supra note 9, at 190.
42. See Widiss, supra note 5, at 1018-25.
43. Michelle Oberman, Mothers and Doctors’ Orders: Unmasking the Doctor’s
Fiduciary Role in Maternal-Fetal Conflicts, 94 NW. U. L. REV. 451, 473-74 (2000).  For 
literature regarding the maternal-fetal conflict after Roe v. Wade more generally see Janet 
Gallagher, Prenatal Invasions and Interventions: What’s Wrong with Fetal Rights, 10 HARV. 
WOMEN’S L.J. 9, 51-53 (1987); see generally Susan Markens et al., Feeding the Fetus: On 
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Recent public health emergencies provide substantial 
reasons to question these assertions and oversights.  The 
approaching anniversaries of these laws have been accompanied 
by major public health emergencies that uniquely affected 
pregnant women and their unborn children.  Pregnant women 
infected with H1N1 were more likely to be hospitalized and die 
from the virus.44  All reported pregnancies in Ebola-infected 
women ended in “spontaneous miscarriage, stillbirth or neonatal 
death.”45  The Zika virus, of course, uniquely attacks fetal tissue, 
resulting in a wide range of serious birth defects that cause death 
and permanent disability.46  These health emergencies brought 
new urgency and focus to the relationship between pregnant 
women and vaccines—and, as argued herein, exposed how 
essentialist critiques applied to the workplace or in the criminal 
context have as much or more force in the advice given to women 
about both routine and emergency vaccinations. 
III. THE SHADOW REGULATORY REGIME FOR
EMERGENCY AND ROUTINE MATERNAL 
VACCINES 
Interrogating the Notion of Maternal-Fetal Conflict, 23 FEMINIST STUD. 351 (1997); 
Lawrence J. Nelson, Legal Dimensions of Maternal-Fetal Conflict, 35 CLINICAL 
OBSTETRICS & GYNECOLOGY 738 (1992); Matthew C. Reid & Grant Gillett, The Case of 
Medea—A View of Fetal-Maternal Conflict, 23 J. MED. ETHICS 19 (1997). 
44.  Sonja A. Rasmussen, Denise J. Jamieson & Joseph S. Bresee, Pandemic Influenza 
and Pregnant Women, 14 EMERGING INFECTIOUS DISEASES 95, 95 (2008) (“Pregnant 
women are at high risk for severe complications of influenza during interpandemic periods 
and previous pandemics.  In addition, some studies suggest an increased risk for adverse 
outcomes among infants born to mothers infected with influenza during pregnancy.”); Sonja 
A. Rasmussen, Denise J. Jamieson & Timothy M. Uyeki, Effects of Influenza on Pregnant 
Women and Infants, 207 AM. J. OBSTETRICS & GYNECOLOGY S3, S3 (2012), 
http://www.ajog.org/article/S0002-9378(12)00722-3/pdf [https://perma.cc/9GY8-H6NJ]. 
45. Benjamin O. Black et al., Ebola Viral Disease and Pregnancy, OBSTETRIC MED.,
Sept. 2015, at 108, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582839/ 
pdf/10.1177_1753495X15597354.pdf [https://perma.cc/5YJ8-EXS6].
46. Microcephaly and Other Birth Defects, CTRS. FOR DISEASE CONTROL & 
PREVENTION, https://www.cdc.gov/zika/healtheffects/birth_defects.html [https:// 
perma.cc/G7NX-B6L4] (“Congenital Zika syndrome is described by the following five 
features: [s]evere microcephaly where the skull has partially collapsed[;] [d]ecreased brain 
tissue with a specific pattern of brain damage[;] [d]amage to the back of the eye[;] [j]oints 
with limited range of motion, such as clubfoot[;] [and t]oo much muscle tone restricting body 
movement soon after birth[.]”); see generally Fernanda R. Cugola et al., The Brazilian Zika 
Virus Strain Causes Birth Defects in Experimental Models, 534 NATURE 267 (2016).  
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There has arguably never been as strong a case for the 
development of a pregnancy-specific (“maternal”) vaccine as 
there is for Zika.47  Discovered in Uganda in 1947, the Aedes 
mosquito-borne virus has long been associated with relatively 
mild symptoms like “fever, muscle aches, eye pain, prostration, 
and maculopapular rash.”48  In 2015, however, a cluster of 
microcephaly cases—a condition that results in a smaller than 
normal head size and sometimes severe disability—was 
discovered in Brazil and quickly associated with the Aedes and 
the Zika virus it carried.49  Not only had the virus evolved to 
attack fetal tissue, but it also demonstrated a potential to infect 
populations at high rates.50  A 2009 study based on antibody 
surveys estimated that an “astonishing” 73% of the population 
had become infected with Zika virus during an outbreak in Yap, 
an island group in the Western Pacific.51  Over 60% of the United 
States’ population lives in areas conducive to seasonal Zika 
transmission, and there are even some that live in areas where 
yearlong Zika transmission is possible.52  During 2016, the CDC 
47. Zika Epidemic Highlights Need for Priority Vaccine Research and Guidelines for
Pregnant Women, EMORY NEWS CTR. (Feb. 24, 2016), http://news.emory.edu /stories 
/2016/02/zika_highlights_need/ [https://perma.cc/ZN W6-74R9]. 
48. Anthony S. Fauci & David M. Morens, Zika Virus in the Americas—Yet Another
Arbovirus Threat, 374 NEW ENG. J. MED. 601, 601-02 (2016); see also Andrew Green, 
Uganda Discovered the Zika Virus. And the Solution For It, FOREIGN POL’Y (Feb. 10, 2016), 
http://foreignpolicy.com/2016/02/10/uganda-discovered-the-zika-virus-and-the-solution-
for-it/ [https://perma.cc/NSR7-7FK7].  
49. Wanderson Kleber de Oliveira et al., Increase in Reported Prevalence of
Microcephaly in Infants Born to Women Living in Areas with Confirmed Zika Virus 
Transmission During the First Trimester of Pregnancy—Brazil, 2015, 65 MORBIDITY & 
MORTALITY WKLY. REP. 242, 242-44 (2016),  https://www.cdc.gov /mmwr/ volumes 
/65/wr/mm6509e2.htm [https://perma.cc/N2TM-UVT2]; One Year into the Zika Outbreak: 
How an Obscure Disease Became a Global Health Emergency, WORLD HEALTH ORG., 
http://www.who.int /emergencies /zika-virus /articles /one-year-outbreak /en/index3.html 
[https://perma.cc/YZQ5-NUVR]. 
50. Rafael A. Larooca et al., Vaccine Protection Against Zika Virus from Brazil, 536
NATURE 474, 474, 477 (2016), http://www.nature.com /nature /journal / vaap/ ncurrent/ full/ 
nature18952.html [https://perma.cc/US4A-FD7F]. 
51. See Mark R. Duffy et al., Zika Virus Outbreak on Yap Island, Federated States of 
Micronesia, 360 NEW ENG. J. MED. 2536, 2536, 2539 (2009), www.nejm.org /doi /pdf 
/10.1056 /NEJMoa0805715 [https://perma.cc/7FPT-9BQ4]; see also Mary Kay Kindhauser 
et al., Zika: The Origin and Spread of a Mosquito-Borne Virus, WORLD HEALTH ORG. (Feb. 
9, 2016), http://www.who.int/bulletin/ online_first/16-171082/en/ [https://perma.cc/RZ8H-
9ZA3]. 
52. Isaac I. Bogoch et al., Anticipating the International Spread of Zika Virus from
Brazil, 387 LANCET 335, 335-36 (2016),   http://www.thelancet.com /journals/ lancet /article 
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reported 224 locally-acquired mosquito-borne cases of the Zika 
virus, and 4,830 travel-associated cases; as of August 8, 2017, 
2,112 pregnant women showed evidence of Zika infection in the 
U.S. alone.53 
Yet, not only have medical researchers made clear they will 
not enroll pregnant women in trials for Zika vaccine candidates, 
but there is, in fact, not a single vaccine specifically licensed for 
use by pregnant women in the United States, for either routine or 
emergency purposes.54  Despite the availability of a detailed 
channel for review and licensing by the FDA, physicians advise 
pregnant women as to recommended vaccinations (both routine 
and emergency) through an alternative regulatory regime that 
emphasizes the role of national technical advisory groups, but not 
double-blind, placebo-controlled clinical trials.  The existence of 
this alternative regulatory pathway is explained by the same 
essentialism that influences other legal regimes: the narrow focus 
on gestation as the touchstone characteristic of pregnancy. 
While FDA review plays an important role in vaccine 
confidence—because vaccines are administered to otherwise 
healthy adults and children, a high standard of safety is 
expected—the upshot of circumventing the FDA for maternal 
vaccines is less access both at the experimental stage and, through 
hesitancy, at the patient stage.55  Perceptions of safety risk, even 
mild ones, may exert a disproportionate effect on the willingness 
/PIIS0140-6736(16)00080-5/abstract [https://perma.cc/8Y3L-KC9F]; see generally Andrew 
J. Monaghan et al., On the Seasonal Occurrence and Abundance of the Zika Virus Vector 
Mosquito Aedes Aegypti in the Contiguous United States, PLOS CURRENTS: OUTBREAKS 
(Mar. 16, 2016), http://currents.plos.org/outbreaks/ article/on-the-seasonal-occurrence-and-
abundance-of-the-zika-virus-vector-mosquito-aedes-aegypti-in-the-contiguous-united-
states/ [https://perma.cc/L8TB-FBCC]. 
53.  2016 Case Counts in the US, CTRS. FOR DISEASE CONTROL & PREVENTION (May 
10, 2017), https:// www.cdc.gov /zika /reporting /2016-case-counts. html [https://perma.cc/ 
7M3N-BVQX]; Pregnant Women with Any Laboratory Evidence of Possible Zika Virus 
Infection in the United States and Territories, CTRS. FOR DISEASE CONTROL & PREVENTION 
(Aug. 8, 2017), https://www.cdc.gov/ zika/reporting/ pregwomen- uscases. html 
[https://perma.cc/KC8L-3L88].  
54. Geeta K. Swamy & R. Phillips Heine, Vaccinations for Pregnant Women, 125
OBSTETRICS & GYNECOLOGY 212, 221 (2015). 
55.  Saad B. Omer & Sam F. Halabi, Evidence, Strategies, and Challenges for Assuring 
Vaccine Availability, Efficacy, and Safety, in GLOBAL MANAGEMENT, supra note 16, at  223, 
228. 
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of pregnant women to accept vaccinations.56  The critical role of 
trust explains the robust regulatory review to which vaccines are 
subjected before licensure as well as the systems in place to search 
for rare adverse events that would not be necessary in the context 
of approval or acceptance for other kinds of pharmaceuticals. 
A. The FDA Approval Process 
The FDA’s Center for Biologics Evaluation and Research 
(CBER) is responsible for regulating vaccines in the United 
States, and its approval facilitates the use of vaccines in countries 
that lack regulatory capacity.57  While vaccine clinical 
development follows the same general pathway as drugs and 
other biologics, the process in place for maternal vaccines has 
never been used.58 
As researchers identify and isolate the relevant pathogen, 
they seek to understand, to the greatest extent possible, the 
biological mechanism or mechanisms that lead to disease.59  Most 
vaccine candidates are developed using empirical approaches—
historically serial propagation of a pathogen through media that 
diminishes pathogenicity or which is killed or dissected after 
56. WORLD HEALTH ORG., REPORT OF THE SAGE WORKING GROUP ON VACCINE
HESITANCY 26 (2014), http://www.who.int /immunization /sage /meetings/ 2014 /october 
/1_ Report_ WORKING_GROUP_vaccine_hesitancy_final.pdf [https://perma.cc/HG66-
78EN]; Allison T. Chamberlain et al., Factors Associated with Intention to Receive Influenza 
and Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccines During Pregnancy: A 
Focus on Vaccine Hesitancy and Perceptions of Disease Severity and Vaccine Safety, PLOS 
CURRENTS: OUTBREAKS (Feb. 25, 2015), http://currents.plos.org/outbreaks/article/factors-
associated-with-intention-to-receive-influenza-and-tetanus-diphtheria-and-acellular-
pertussis-tdap-vaccines-during-pregnancy-a-focus-on-vaccine-hesitancy-and-perceptions-
of/ [https://perma .cc/5LJR-VATG]. 
57. See Vaccine Product Approval Process, FOOD & DRUG ADMIN.,
http://www.fda.gov/biologicsbloodvaccines/developmentapprovalprocess/biologicslicensea
pplicationsblaprocess/ucm133096.htm (last accessed Aug. 26, 2017) [https:// 
perma.cc/92WU-PTEM]; Michael J. Brennan, The US Food and Drug Administration 
Provides a Pathway for Licensing Vaccines for Global Diseases, PLOS MED. (Jul. 21, 2009), 
http:// journals.plos.org /plosmedicine /article?id= 10.1371/journal.pmed.1000095 
[https://perma.cc/S3XD-6A59]. 
58. 42 U.S.C. § 262(i), (k) (2012); see also FOOD & DRUG ADMIN., CLINICAL 
DEVELOPMENT AND REQUIREMENTS FOR LICENSURE OF VACCINES INTENDED FOR USE 
DURING PREGNANCY TO PREVENT DISEASE IN THE INFANT 3 (2015) [hereinafter CLINICAL 
DEVELOPMENT]. 
59. PRINCIPLES OF BACTERIAL PATHOGENESIS, at xv (Eduardo A. Groisman ed.,
2001). 
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cultivation and used in relatively large doses.60  More recent 
techniques like “reverse vaccinology” start from “genomic 
sequences” and, by computer simulation, predict “those antigens 
that are most likely to be vaccine candidates.”61  Vaccine 
candidates are then tested in animals after developing models for 
immunogenicity and safety. 
After satisfactory animal testing, the FDA authorizes the 
sponsor to undertake clinical trials on humans.  Phase I of these 
trials “is designed to assess the safety, immunogenicity, and dose 
response of the vaccine in, typically, 20 to 100 healthy 
volunteers.”62  In Phase II, the sample size is increased to several 
hundred healthy volunteers and investigators focus on safety as 
well as immunogenicity.63  Phase III vaccine trials enroll up to 
thousands of human subjects in order to detect sometimes rare 
adverse events.64  If Phase III trials “confirm safety and 
efficacy . . . the vaccine is approved for marketing after internal 
review of study data.”65 
In addition to pre-licensure vaccine clinical trials, the FDA 
requires a biologics license application, inspection of the 
manufacturing facility, presentation of findings to the FDA’s 
Vaccines and Related Biological Products Advisory Committee, 
and usability testing of product labeling.66  The ’Vaccines and 
Related Biological Products Advisory Committee “reviews and 
evaluates data” to determine “safety, effectiveness, and 
60. Nicola P. Klein et al., Waning Protection After Fifth Dose of Acellular Pertussis
Vaccine in Children, 367 NEW ENG. J. MED. 1012, 1013 (2012), http://www. 
nejm.org/doi/pdf/10.1056/NEJMoa1200850 [https://perma.cc/FA8C-W3B7]; Bo Ma et al., 
Characteristics and Viral Propagation Properties of a New Human Diploid Cell Line, 
Walvax-2, and Its Suitability as a Candidate Cell Substrate for Vaccine Production, 11 HUM. 
VACCINES & IMMUNOTHERAPEUTICS 998, 1004-05 (2015). 
61. Rino Rappuoli, Reverse Vaccinology, a Genome-Based Approach to Vaccine
Development, 19 VACCINE 2688, 2689 (2001).  
62.  Omer & Halabi, supra note 55, at 225; see also 21 C.F.R. § 312.23(a)(6)(i) (2016).
63. Phase II Trial: About Phases of Clinical Trials, U.S. NAT’L INSTS. HEALTH,
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0022683/ [https://perma.cc/WN6 H-
HWD2]. 
64. L. Simonsen et al., More on RotaShield and Intussusception: The Role of Age at
the Time of Vaccination, 192 J. INFECTIOUS DISEASES S36, S37 (2005), 
https://academic.oup.com/jid/article-lookup/doi/10.1086/431512 [https://perma.cc/VA 2Z-
8DRC]. 
65. See Omer and Halabi, supra note 55, at 226.
66. Vaccine Testing and the Approval Process, CTRS. FOR DISEASE CONTROL & 
PREVENTION, http:// www.cdc.gov /vaccines /basics /test-approve.html [https:// perma.cc 
/ZE3B-GA65]. 
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appropriate use of vaccines.”67  Members and the Chair are 
selected by the Commissioner or designee from among 
“authorities knowledgeable in the fields of immunology, 
molecular biology, rDNA, virology[,] bacteriology, 
epidemiology or biostatistics, vaccine policy, vaccine safety 
science, federal immunization activities, vaccine development 
including translational and clinical evaluation programs, allergy, 
preventive medicine, infectious diseases, pediatrics, 
microbiology, and biochemistry.”68  The committee reviews 
vaccinations as one of the final steps before approval by the 
FDA.69 
B. Requirements for Vaccines Intended for Use During 
Pregnancy 
Under guidelines issued by the FDA, additional 
requirements apply to vaccines developed for use during 
pregnancy.  Animal testing and clinical testing must be specified 
to address the potential reproductive risk of the product before 
enrolling any pregnant women into clinical trials.70  Phase I 
clinical trials for maternal immunizations begin with non-
pregnant women of childbearing age.71  If results of the proposed 
vaccination are positive, studies of the vaccination may be 
advanced into early studies of pregnant women classified as low-
risk.72  If adequate data from Phase I clinical trials of pregnant 
women is observed, Phase II may begin to identify a “pilot 
evaluation of efficacy.”73  As with Phase III trials generally, trials 
for vaccine candidates intended for use during pregnancy are 
required to use a prospective, randomized, blinded, well-
controlled study, wherein the control arm receives a placebo (or 
unrelated vaccine) and the primary endpoint is prevention of 
67. Vaccines and Related Biological Products Advisory Committee, FOOD & DRUG 
ADMIN., http://www.fda.gov /AdvisoryCommittees /CommitteesMeeting Materials 
/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryComm
ittee/default.htm [https://perma.cc/J44K-E98Q]. 
68. Id.
69. Vaccine Product Approval Process, supra note 57.
70. Roberts & Gruber, supra note 18, at 968.
71. Id.
72. Id.
73. Id.
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clinical disease in a wider population of pregnant women (not 
limited to low-risk pregnancies).74  After clinical development 
stages, the vaccination would advance to the licensing 
application, where FDA reviewers would assess the information 
necessary to make a risk/benefit decision and a recommendation 
for the approval of the vaccine.75 
Safety evaluations are incredibly important during each 
phase of the clinical trials, but continue after the approval of the 
vaccine.76  It is essential to develop a systematic approach to 
classifying adverse events to be able to assess causality when an 
adverse event is observed in the clinical trial.77  Until a vaccine is 
given to the general population, all potential adverse reactions 
cannot be anticipated.78  Thus, many vaccines undergo Phase IV 
studies once on the market, and strict safety reporting standards 
are in place during and after clinical trials.79  A key criterion 
during Phase IV studies is to determine if there is a “reasonable 
possibility that the drug (or biologic) caused [an adverse] event 
and whether the event (or pattern of events) is unexpected.”80  
During general population use of the vaccination, it may be 
necessary to develop a pregnancy registry in order to explore 
potential changes and improve the quality and utility of the 
vaccination.81 
C. Labeling 
Approval of vaccines “also requires . . . adequate product 
labeling to allow health care providers to understand the vaccine’s 
74. Id.
75. 42 U.S.C. § 262(k) (2012); Vaccine Product Approval Process, supra note 57.
76. See Vaccine Product Approval Process, supra note 57.
77. Roberts & Gruber, supra note 18, at 969; Alberto E. Tozzi et al., Assessment of
Causality of Individual Adverse Events Following Immunization (AEFI): A WHO Tool For 
Global Use, 31 VACCINE 5041, 5041-5042 (2013), http://www.sciencedirect.com /science 
/article /pii /S0264410X13011997 [https://perma .cc/P7JT-MZL9]. 
78. See Vaccine Product Approval Process, supra note 57.
79.  Id.; see also Geert Leroux-Roels et. al., Vaccine Development, 1 PERSPECTIVES IN
VACCINOLOGY 115, 123 (2011) (“Phase IV surveillance studies, because of the large sample 
size involved, are designed to detect very rare adverse events (AEs) that are difficult to pick 
up in Phase III studies.”).   
80. Roberts & Gruber, supra note 18.
81. Id. at 969; see generally Eileen Wilson et al., Varicella Vaccine Exposure During
Pregnancy: Data from 10 Years of the Pregnancy Registry, 197 J. INFECTIOUS DISEASES 
S178 (2008). 
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proper use, including its potential benefits and risks, to 
communicate with patients and parents, and to safely deliver the 
vaccine to the public.”82  A product’s package insert, also known 
as the label, is a critical element of the evaluation of a 
vaccination.83  Vaccine labels must include a section for usage 
during pregnancy.84 
Until recently, information on a product insert was 
categorized using a letter system under which each letter 
represented the relative availability of clinical information.85  
Category A pharmaceuticals were those, like folic acid 
supplements, where “adequate and well-controlled studies failed 
to demonstrate a risk to the fetus in the first trimester of 
pregnancy.”86  Category B pharmaceuticals meant that there were 
no adequate and well-controlled studies over human pregnancy, 
but animal data was reassuring, while Category C 
pharmaceuticals meant that there were no adequate and well-
controlled human studies and also no positive animal data.87  
Categories D and X conveyed “fetal risk [in] investigational or 
marketing . . . studies . . . .”88 
The FDA recently revised the regulations for the 
characterization of a drug or biologic as it affects pregnancy and 
issued the Pregnancy and Lactation Labeling Rule (“PLLR”).89  
The PLLR changed the labeling rule for biologics (e.g. vaccines) 
and pharmaceuticals from categorizing risks into lettered 
categories (A, B, C, D, and X) to providing “a narrative summary 
of the risks of using [the] drug or biological product during 
pregnancy.”90  The new rule not only requires that this 
82. See Vaccine Product Approval Process, supra note 57; see also INST. OF MED., 
THE CHILDREN’S VACCINE INITIATIVE: ACHIEVING THE VISION 164-69 (Violaine S. 
Mitchell et al. eds., 1993).  
83. See generally 21 C.F.R. §§ 201.56-.57 (2016).
84. Requirements for Pregnancy and Lactation Labeling, 79 Fed. Reg. 72,064, 72,064 
(Dec. 4, 2014) (to be codified at 21 C.F.R. pt. 201). 
85. Marion F. Gruber, The US FDA Pregnancy Lactation and Labeling Rule—
Implications for Maternal Immunization, 33 VACCINE 6499, 6500 (2015). 
86. U.S. Dep’t of Health & Human Servs., FDA Pregnancy Categories, CHEMM,
https://chemm.nlm.nih.gov/pregnancycategories.htm [https://perma.cc/ 3MWN-T37U].  
87. Id.
88. Id.
89. See generally Requirements for Pregnancy and Lactation Labeling, 79 Fed. Reg.
72,064 (Dec. 4, 2014) (to be codified at 21 C.F.R. pt. 201). 
90. Gruber, supra note 85, at 6499-500.
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information be adapted to be given in narrative form, but also that 
the labeling “include . . . clinical information to help health care 
providers make prescribing decisions and counsel women about 
the use of drugs during pregnancy . . . .”91 
Even under the new system, the relative risk to pregnant 
women considering use is opaque.  Consider the product insert 
language for a seasonal influenza vaccine still marketed under 
Category B: 
There are . . . no adequate and well-controlled studies in 
pregnant women. Because animal reproduction studies are 
not always predictive of human response, this vaccine should 
be used during pregnancy only if clearly needed.92 
Or the language for vaccines approved under the new rule: 
Available data on Prevnar 13 administered to pregnant 
women are [sic] insufficient to inform vaccine-associated 
risks in pregnancy.93 
As analyzed below, the continuing difficulty in obtaining 
relevant information about vaccines during pregnancy—and the 
resulting effect on product labeling—is not the result of a more 
comprehensive or objective approach to pregnancy.  Rather, it is 
a continuation of culturally informed conceptions inseparable 
from those influencing regimes dedicated to antidiscrimination, 
prosecution, or family support. 
D. The Alternative Regulatory Framework for 
Maternal Vaccines 
Despite FDA guidance on approval of maternal vaccines 
through normal channels, the system is unused.  Instead, the 
approval for maternal vaccines is effectively allocated to national 
technical advisory groups like the Advisory Committee on 
Immunization Practices (ACIP), a statutory body established to 
91. Id.
92. SEQIRUS INC., FLUVIRIN PRODUCT INSERT (2017), http://www.fda.gov /
downloads /BiologicsBloodVaccines /Vaccines /ApprovedProducts /UCM123694.pdf 
[https://perma.cc/78V3-SH5H].   
93.  PFIZER INC., PREVNAR PRODUCT INSERT (2017), http:// www. fda.gov /downloads
/Biologics Blood Vaccines /Vaccines /ApprovedProducts /UCM201669.pdf 
[https://perma.cc/T34B-H6P2]; see also Guidelines for Vaccinating Pregnant Women, CTRS. 
FOR DISEASE CONTROL & PREVENTION (2016), https://www.cdc.gov /vaccines /pregnancy 
/hcp/guidelines.html [https://perma.cc/M24N -8ULB]. 
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“develop recommendations on the use of vaccines in the civilian 
population of the United States.”94  The 15 member steering 
committee is appointed by the Secretary of Health and Human 
Services after “an application and nomination process,” with 14 
of the 15 members being medical experts and one serving as a 
consumer representative.95  The committee reports to the Director 
of the CDC.96 
ACIP provides assistance to the CDC “regarding the most 
appropriate selection of vaccines and related agents for effective 
control of vaccine-preventable diseases.”97  It also addresses 
issues of specific populations such as pregnant and breastfeeding 
women.98 
The committee votes on whether to include a new vaccine in 
the routine immunization schedule, vaccine use in high risk 
groups, and use of vaccines outside the routine 
schedules . . . . For each recommended vaccine, the 
committee develops written guidance, subject to the 
approval of the CDC Director, for administration of FDA-
licensed vaccines to children and adults in the US civilian 
population, including age for vaccine administration, dose 
and frequency of administration, and precautions and 
contraindications of vaccine use and information on adverse 
events.99   
ACIP uses work groups to investigate data, which the groups 
then present to the committee.100  These work groups “focus on 
one vaccine or group of vaccines,” and formulate proposed policy 
options by “review[ing] data on morbidity and mortality 
94. About ACIP, CTRS. FOR DISEASE CONTROL & PREVENTION (Apr. 15, 2016),
https://www.cdc.gov/vaccines/acip/about.html [https://perma.cc/F46Q-NKXL]; see also 42 
U.S.C. § 2l7(a) (2012). . 
95. See About ACIP, supra note 94.
96. ACIP: Guidance for Vaccine Recommendations for Pregnant and Breastfeeding
Women, CTRS. FOR DISEASE CONTROL & PREVENTION [hereinafter Vaccine 
Recommendations], https://www.cdc.gov/vaccines/acip/committee/guidance/ rec-vac-
preg.html [https://perma.cc/6BSY-W4ES]. 
97. Id.
98. Id.
99. Jean Clare Smith, The Structure, Role, and Procedures of the U.S. Advisory
Committee on Immunization Practices (ACIP), 28S VACCINE A68, A71 (2010), 
http://www.sciencedirect.com/science/article/pii/S0264410X10002057 [https://perma. 
cc/4T69-G3WW].   
100.  Id. at A72. 
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associated with the disease in the general US population and in 
specific risk groups.”101 
While its statutory authority falls within broadly worded 
provisions aimed at the role of the CDC in preventing 
communicable diseases, ACIP’s authority to recommend 
unlicensed vaccines comes from its charter—a document that is 
required to be filed under the Federal Advisory Committee Act, 
but is otherwise of uncertain legal status.102  Under ACIP’s 
charter, “[g]uidance for use of unlicensed vaccines may be 
developed if circumstances warrant.  For each vaccine, the 
committee advises on population groups and/or circumstances in 
which a vaccine or related agent is recommended.”103  Similarly, 
professional organizations like the American Congress of 
Obstetricians and Gynecologists, which serve as liaison 
organizations to ACIP, develop immunization recommendations 
for practitioners that are guided by, but not necessarily 
coextensive with, labeling recommendations.104  The FDA, in 
turn, allows these recommendations to substitute for regulatory 
review, declaring that “programmatic recommendations (such as 
those from WHO, ACIP, and other national immunization 
technical advisory groups (NITAGs)) for use during pregnancy 
are not inconsistent with FDA labeling.”105 
In March 2008, ACIP approved its Guiding Principles in 
Development of ACIP Recommendations for Vaccination During 
Pregnancy and Breastfeeding.106  Previously, ACIP did not 
provide any direction to technical advisory groups about creating 
policy for vaccination use during pregnancy,107  so those groups 
adopted recommendations that “var[ied] in clarity and underlying 
101.  Id. 
102.  CTRS. FOR DISEASE CONTROL & PREVENTION, CHARTER OF THE ADVISORY 
COMMITTEE ON IMMUNIZATION PRACTICES 1 (2016), https://www.cdc.gov /vaccines /acip 
/committee /acip-charter-2016.pdf [https://perma. cc/K9FM-YTLP]. 
103.  Id. at 2.   
104.  See, e.g., ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP), 
SUMMARY REPORT 6, 10, 23-24 (2012), https://www.cdc.gov/ vaccines /acip /meetings 
/downloads/min-archive/min-oct12.pdf [https://perma.cc/WF7 D-YNDD]; Jean Clare Smith 
et al., History and Evolution of the Advisory Committee on Immunization Practices—United 
States, 1964-2014, 63 MORBIDITY & MORTALITY WKLY. REP. 955, 956 (2014).  
105.  CLINICAL DEVELOPMENT, supra note 58, at 10. 
106.  Vaccine Recommendations, supra note 96. 
107.  Id. 
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rationale.”108  Generally, “[o]bstetrician-gynecologists (ob-gyns) 
provide more general medical care to women than either family 
practice or internal medicine providers, and” therefore have better 
“opportunities to incorporate vaccination into standard clinical 
care.”109 
It is through this system that a fairly small number of 
vaccinations have been generally accepted for use during 
pregnancy.110  ACIP, for example, recommends that all pregnant 
women receive Tdap and seasonal influenza vaccinations, even 
though they are not licensed for use during pregnancy.111  Some 
other vaccinations may be recommended based on travel or 
specific patient profiles, but, as with influenza and Tdap, none 
have been specifically tested in pregnant women.112 
Safety data for maternal immunization is largely gathered 
through post-vaccination adverse event monitoring systems, 
including pregnancy registries and Phase IV post-immunization 
studies.  For example, the Vaccine Adverse Event Reporting 
System (“VAERS”) collects and analyzes information from 
reports of negative side effects that occur during the 
administration of U.S. licensed vaccines.113  This program, co-
sponsored by the FDA and the CDC, receives around 15,000 
reports per year.114  Because of this program, “researchers detect 
new or rare events, identify increases in rates of known side 
effects, and enhance understanding of patient risk factors.”115  
The Vaccine Safety Datalink (“VSD”), run cooperatively by nine 
healthcare organizations and the CDC, “monitor[s] safety of 
vaccines and conduct[s] studies about rare and serious adverse 
events following immunization . . . based on questions or 
108.  Id.  
109.  Swamy & Heine, supra note 54, at 212-13. 
110.  See id. at 214. 
111.  Maternal Vaccines: Part of a Healthy Pregnancy, supra note 19; Swamy & 
Heine, supra note 54, at 221 (“To date, vaccines in the United States are not specifically 
licensed or targeted for use during pregnancy.”). 
112.  See Swamy & Heine, supra note 54, at 214, 221. 
113.  Vaccine Adverse Event Reporting System, U.S. DEP’T OF HEALTH & HUM. 
SERVS., https://vaers.hhs.gov/index [https://perma.cc/D7ML-J9RX]. 
114.  U.S. FOOD & DRUG ADMIN., REVIEW OF VAERS ANTHRAX VACCINE REPORTS 
RECEIVED THROUGH 8/15/05, AND ADVERSE EVENT REPORTS SUBMITTED TO DOCKET NO. 
1980N-0208, at 1-2 (2005), http://www.fda.gov/ohrms/ dockets/dockets/80n0208/80n-
0208-bkg0006-19-Ref-17-VAERS-Vol225.pdf [https:// perma.cc/87ZZ-F66Q]. 
115.  See Halabi & Omer, supra note 55, at 229. 
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concerns raised from the medical literature and reports to the 
[VAERS].”116  The results from each data collection program are 
“linked with larger databases like the CDC’s Clinical 
Immunization Safety Assessment Network (CISA), which 
provides a clinical case evaluation service for US healthcare 
providers who have vaccine safety questions.”117 
IV. SHADOW REGULATION OF MATERNAL
VACCINES AND THE FUTURE OF MATERNAL AND 
INFANT HEALTH 
As with analogues in Pregnancy Discrimination Act 
jurisprudence and the reach of the Family Medical Leave Act, the 
shadow regulatory system for approving vaccines for use during 
pregnancy does not reflect the consensus in the medical literature 
regarding pregnant women’s participation in clinical trials, 
protections for mothers and fetuses codified in federal law, or the 
potential value of maternal vaccines for the future of human 
health.  It reflects a narrow view of pregnancy that focuses on 
gestation instead of looking comprehensively at the social and 
medical changes that accompany pregnancy. 
Although there is substantial evidence to support the use of 
vaccines to prevent diseases in mothers and infants, there has 
historically been little interest in developing vaccines for use 
during pregnancy.118  Maternal immunization strategies have 
been proven to protect infants against neonatal tetanus, and to 
protect mothers and infants against influenza and pertussis.119  
There have not been any safety concerns identified with regard to 
vaccinating women during pregnancy, but regulatory barriers 
such as evaluating efficacy and safety pose a limitation.120 
116.  Vaccine Safety Datalink (VSD), CTRS. FOR DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/ 
[https://perma.cc/QZN3-6U24].  
117.   Halabi & Omer, supra note 55, at 230. 
118.  See K. Zaman et al., Effectiveness of Maternal Influenza Immunization in 
Mothers and Infants, 359 NEW ENG. J. MED. 1555, 1555-1563 (2008), http://www.ne 
jm.org/doi/full/10.1056/NEJMoa0708630#t=article [https://perma.cc/ BV8R-ZZB8]; see 
generally Swamy & Heine, supra note 54. 
119.  Flor M. Munoz, Respiratory Syncytial Virus in Infants: Is Maternal Vaccination 
a Realistic Strategy?, 28 CURRENT OPINION INFECTIOUS DISEASES 221, 223 (2015). 
120.  See Roberts & Gruber, supra note 18, at 966. 
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Federal law authorizes the inclusion of pregnant women in 
medical research and conditions authorization on several criteria 
related to the risk and benefit for both mother and fetus.121  
Despite the care taken within federal regulations to facilitate 
participation of pregnant women and implement a meaningful 
risk/benefit framework, researchers “reflexively exclude” 
pregnant women from clinical research aimed at discovering safe 
and effective vaccines.122  While researchers must justify the 
inclusion of pregnant women in a research protocol and specify 
what special protections will be implemented, there is no 
requirement to justify their exclusion.123  Since the U.S. National 
Institutes of Health (NIH) began to require inclusion of women, 
ethnic minorities, and children in research, pregnant women are 
the only population for which justification for exclusion does not 
need to be given.124 
The reasons for excluding pregnant women are consistent 
with the essentialist critique leveled against legal regimes aiming 
to protect pregnant women from employment discrimination, to 
support them comprehensively during and after pregnancy, and to 
selectively promote or punish certain behaviors during 
pregnancy.  In their path breaking work on barriers to inclusion 
of pregnant women in medical research, a joint NIH/FDA team 
led by Mary Blehar concluded that: 
[R]easons [for excluding pregnant women] include  . . . fear 
of harm to the fetus and threat of legal liability, concern 
about the complicated physiology of pregnant women, 
uncertainty whether pregnant women would be willing to 
participate, regulations which classify pregnant women as a 
‘vulnerable’ population in need of special protections in 
research, and vague, ambiguous, and restrictive wording of 
121.  45 C.F.R. §§ 46.201-.211 (2016); Vanessa Merton, Impact of Current Federal 
Regulations on the Inclusion of Female Subjects in Clinical Studies, in 2 WOMEN AND 
HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES OF INCLUDING WOMEN IN CLINICAL 
STUDIES 65, 67-68 (Anna C. Mastroianni, Ruth Faden & Daniel Federman eds., 1994); 
COMM. ON THE ETHICAL AND LEGAL ISSUES RELATING TO THE INCLUSION OF WOMEN IN 
CLINICAL STUDIES, INST. OF MED., 1 WOMEN AND HEALTH RESEARCH: ETHICAL AND 
LEGAL ISSUES OF INCLUDING WOMEN IN CLINICAL STUDIES 142 (Anna C. 
Mastroianni, Ruth Faden, & Daniel Federman eds., 1994). 
122.  Mary C. Blehar et al., Enrolling Pregnant Women: Issues in Clinical Research, 
23 WOMEN’S HEALTH ISSUES e39, e40 (2013).  
123.  Id. at e42. 
124.  Id. 
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regulations, which IRBs in turn interpret conservatively for 
pregnant subjects.125 
In their study of industry trials specifically, Kristine Shields and 
Anne Lyerly found that only 1% of studies were designed 
specifically for pregnant women, and 95% of studies of 
conditions that can affect pregnant women excluded pregnant 
women from participation.126  Those studies were Phase IV 
studies undertaken as retrospective analyses.127  As they note: “A 
common explanation for the exclusion of pregnant women from 
research is the desire to ‘do no harm,’ yet clinical care during 
pregnancy often requires the use of medications untested in 
pregnancy.”128  This is true in the context of Zika as well, where 
even promising vaccine candidates, if proven safe and effective, 
are likely to be administered to women or adolescent girls who 
are not pregnant.129 
These exclusions have multiple ramifications for both 
maternal and infant health.130  Because pregnant women are 
excluded from vaccine research, the information that 
accompanies even recommended vaccines—like seasonal 
125.  Id. at e40.  
126.  Kristine E. Shields & Anne Drapkin Lyerly, Exclusion of Pregnant Women From 
Industry-Sponsored Clinical Trials, 122 OBSTETRICS & GYNECOLOGY 1077, 1077 (2013). 
127. Viraj Suvarna, Phase IV of Drug Development, 1 PERSP. CLINICAL RES. 57, 59 
(2010) (“Some of these studies may be retrospective case-control evaluations. These are 
done to evaluate rare suspected side effects.”). 
128.  Shields & Lyerly, supra note 126, at 1080. 
129.  WORLD HEALTH ORG., WHO/UNICEF ZIKA VIRUS (ZIKV) VACCINE TARGET 
PRODUCT PROFILE (TPP): VACCINE TO PROTECT AGAINST CONGENITAL ZIKA SYNDROME 
FOR USE DURING AN EMERGENCY 1, 6 (2017), http://www. 
who.int/immunization/research/development/WHO_UNICEF_Zikavac_TPP_Feb2017.pdf  
[https://perma.cc/U93U-S3K6] (“It is not expected that initial products would contain an 
indication for use in pregnant women.”); Hilary D. Marston et al., Considerations for 
Developing a Zika Virus Vaccine, 375 NEW ENG. J. MED. 1209, 1209-12 (2016) (“Second, 
vaccine safety and immunogenicity are generally established in nonpregnant adults before 
vaccination of pregnant women is considered—a standard practice that delays vaccine use 
in the latter population until some assurances of safety are provided.  Hence, it is likely that 
vaccinating women of childbearing age (and men in order to prevent sexual transmission) 
would be the optimal initial public health strategy.  In the longer term, it may be advisable 
to vaccinate pediatric populations, well before their first sexual contact.  Here, the experience 
with rubella is instructive: protection of pregnant women was achieved through broad 
vaccination of young children. Adoption of this strategy would depend on the durability of 
protection offered by a Zika vaccine.”). 
130.  Saad B. Omer & Richard H. Beigi, Pregnancy in the Time of Zika: Addressing 
Barriers for Developing Vaccines and Other Measures for Pregnant Women, 315 JAMA 
1227, 1227-1228 (2016). 
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influenza and Tdap—confuses many physicians and depresses 
uptake by pregnant women who justifiably question the safety 
and efficacy profile of the immunizations.  The reflexive 
exclusion of pregnant women, without justification, deters the 
development of a meaningful risk/benefit framework to apply to 
research even where vaccines may do much to address infections, 
like RSV and Group B Strep infection that pose serious risks to 
infants. 
A. The Development of an Ethical Framework and 
Risk-Benefit Analysis 
Medical researchers and institutional review boards 
(“IRBs”—also known as “independent ethics committees”—
assure that appropriate steps are taken to protect the rights 
and welfare of humans participating as research subjects) have 
largely dodged risk, benefit, and ethics decisions involving 
research on pregnant women.131  Federal law, under “Subpart B” 
regulations, requires that risks and benefits be assessed when 
undertaking research with pregnant women volunteers, including 
the nature and quality of informed consent communications, the 
definition of “important biomedical knowledge,” and the research 
alternatives, if any, to specific medical interventions.132  Because 
pregnant women are reflexively excluded, often without 
explanation, there are confused and competing interpretations of 
what these principles might mean.133 
131.  Institutional Review Boards Frequently Asked Questions—Information Sheet, 
U.S. FOOD & DRUG ADMIN., http://www.fda.gov/RegulatoryInformation/ 
Guidances/ucm126420.htm [https://perma.cc/4TK8-J8ZY]. 
132.  See 45 C.F.R. §§ 46.203-.204 (2016). 
133.  See, e.g., IRB Assessment of Risk & Benefit for Research Involving Pregnant 
Women and Fetuses (Subpart B), U.C.-IRVINE (Mar. 2013), http://www. research.uci.edu 
/compliance/human-research-protections/docs/pregnant-women-fetus-neonates-laminated-
sheet.pdf [https://perma.cc/DBC2-SBCR ] (“The risk to the fetus is not greater than minimal 
and the purpose of the research is the development of important biomedical knowledge which 
cannot be obtained by any other means.  Only Mother’s consent is required. NOTE: For DoD 
supported research, there are exceptions (e.g., the phrase ‘biomedical knowledge’ in subpart 
B shall be replaced with ‘generalizable knowledge’ throughout the subpart). Refer to DoDI 
3216.02, version November 8, 2011.” (emphasis omitted)); Janice K. Bush, The Industry 
Perspective on the Inclusion of Women in Clinical Trials, 69 ACAD. MED. 708, 712-14 
(1994) (detailing conflicting principles with respect to pregnancy and clinical trials). 
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“Minimal risk” is a concept that informs the ethical review 
of research and is poorly defined in the Subpart B context.134  
IRBs often categorize research in pregnancies as “high risk” 
without any meaningful development of a decision framework.135  
The lack of a broadly accepted ethical framework and definition 
of risk for guiding clinical research during pregnancy has a 
limiting effect on both academic and industry-led clinical trials 
regarding the Zika virus.136  The lack of an ethical framework has 
a chilling effect on clinical research in pregnancy and could lead 
to a similar effect for research of the Zika vaccine because the 
virus has implications for pregnant women and women of 
reproductive age.137 
Definitions of “risk” and “direct benefit” for both mothers 
and fetuses are crucial for this fundamental scientific endeavor.138  
For example, researchers cannot identify appropriate animal 
models during development research without a framework under 
which their interventions will be assessed later.139 
Public health emergencies magnify the need for these 
definitions because they require a real-time assessment of 
risks.140  For example, in 2009, during the H1N1 influenza 
pandemic, the risks of disease greatly outweighed the expected 
risks from the vaccination of pregnant women, which led to much 
needed insight on necessary improvements in research.141  These 
challenges included the need for further articulation of baseline 
rates, which would define relevant, expected clinical and 
laboratory standards in pregnancy, and the need for accurate 
assignment of pregnancy complications.142  The baseline rate of 
outcomes is extremely important when a disease emerges that is 
associated with adverse birth outcomes, and development of these 
baseline rates could generate large multi-location data sets that 
134.   See Omer & Beigi, supra note 130, at 1227. 
135.  Id.   
136.  Id. 
137.  Id.   
138.  See generally Seema Shah et al., How Do Institutional Review Boards Apply the 
Federal Risk and Benefit Standards for Pediatric Research?, 291 JAMA 476 (2004), http:// 
jama. jamanetwork.com /article. aspx ?article id = 198070 &result click =1 [https://perma.cc/ 
PWS8-ZQLF]. 
139.  See Beigi et al., supra note 17, at 4262. 
140.  See Omer & Beigi, supra note 130, at 1228. 
141.  See Beigi et al., supra note 17, at 4262. 
142.  Id.  
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would optimize the evaluation of clinically important outcomes, 
such as microcephaly.143  The Ebola public health emergency 
illustrates the dilemma posed by the absence of meaningful 
frameworks for ethical review, risk, and benefit.  Pregnant women 
were excluded from Ebola vaccine trials even though all reported 
pregnancies in Ebola infected women ended in spontaneous 
miscarriage, stillbirth or neonatal death.144 
B. Toward a More Comprehensive Understanding of 
Pregnancy and Its Outcomes 
1. Immunity and Early Pregnancy
Most of the current knowledge about vaccine response 
comes from studies conducted in the latter part of pregnancy.145  
Pregnancy is a “physiologically dynamic state” and the immune 
profile of a pregnant women is responsive to changing levels of 
sex hormones throughout different stages of pregnancy.146  Yet 
there is “limited data available from the first and early second 
trimester[s]” or from randomized clinical studies, even for 
vaccines now recommended by ACIP.147  For example, while it 
is known that pertussis immunization during pregnancy confers 
protection on newborns, the “effectiveness and optimal 
concentration of maternal antipertussis antibodies in newborns” 
is not.148  High levels of antibodies in the first weeks after birth 
likely confer protection and might prevent pertussis or modify 
disease severity, but a great deal remains unknown.149  Similarly, 
there are knowledge gaps with respect to the impact of the timing 
143.  See Omer & Beigi, supra note 130, at 1228. 
144.  LEONTINE ALKEMA ET AL., TRENDS IN MATERNAL MORTALITY: 1990 TO 2015, 
at 26 (2015), http://apps.who.int/iris/bitstream/10665/112682/2/9789241507 226_eng.pdf 
[https://perma.cc/75QL-PWCE]; Black et al., supra note 45, at 108; Agence Fr.-Presse, A 
New Ebola Vaccine May Be ‘Up to 100 Percent Effective’, PUB. RADIO INT’L (Dec. 24, 2016, 
11:15 AM), https:// www. pri.org /stories/ 2016-12-24/ new- ebola- vaccine- may- be- 100-
percent -effective [https://perma.cc/C35X-3CKA]. 
145.  See Omer & Beigi, supra note 130, at 1227.  
146.  Id.   
147.  Id.; see also CLINICAL DEVELOPMENT, supra note 58, at 3.   
148.  Mark Sawyer et al., Updated Recommendations for Use of Tetanus Toxoid, 
Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women, 
62 MORBIDITY & MORTALITY WKLY. REP. 131, 131 (2013), https://www.cdc.gov /mmwr 
/preview /mmwrhtml /mm6207a4.htm [https://perma.cc/BJ 3S-PKZQ].   
149.  Id. 
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of Tdap during pregnancy on infant pertussis, the safety of 
multiple doses of the vaccine in pregnant women, and its overall 
effectiveness.150  With respect to influenza, the medical 
community lacks understanding of how different strains of the 
influenza virus affect mothers and newborns differently.151 
The Zika emergency highlights the need for better 
understanding: the harmful effects of Zika virus infection likely 
occur in the early parts of pregnancy, so a Zika vaccine may work 
best if administered prior to pregnancy or early in pregnancy.152  
Zika’s link to fetal development highlights the need for pregnant 
women and those of reproductive age to be a priority while 
moving forward in the developmental stages of this vaccine.153 
2. Understanding Background Events and
Outcomes 
Because pregnancy is conceptualized as it is at the IRB 
level—a physiological process that should result in the birth of a 
healthy baby—there is in fact inadequate understanding of 
population level phenomena related to adverse outcomes that 
would be necessary to adequately study maternal vaccines.  A 
major barrier in the approval of pregnancy-specific vaccinations 
is the inability to arrive at a “definite etiology for reproductive 
effects such as congenital malformations and spontaneous 
abortions.”154  Only one-third of malformed children can be 
provided with a diagnosis, and 15% percent of all pregnancies 
result in spontaneous abortions.155  Another challenge is that these 
150.  Bahaa Abu Raya et al., The Effect of Timing of Maternal Tetanus, Diphtheria, 
and Acellular Pertussis (Tdap) Immunization During Pregnancy on Newborn Pertussis 
Antibody Levels—A Prospective Study, 32 VACCINE 5787, 5790-92 (2014); see also 
CLINICAL DEVELOPMENT, supra note 58, at 9-10; Sawyer et al, supra note 148, at 131-32. 
151.  Sarah J. Short et al., Maternal Influenza Infection During Pregnancy Impacts 
Postnatal Brain Development in the Rhesus Monkey, 67 BIOLOGICAL PSYCHOL 965, 971 
(2010). 
152.  See Omer & Beigi, supra note 130, at 1227. 
153.   Ian Sample, Zika Virus Vaccine for Animals Brings Hope for Human Protection, 
GUARDIAN (June 28, 2016, 11:00 AM), https://www.theguardian.com/ world/ 2016/ jun/28 
/zika-virus-vaccine-for-animals-brings-hope-for-human-protection [https://perma.cc/ARE7-
93QZ]. 
154.  Robert L. Brent, Immunization of Pregnant Women: Reproductive, Medical and 
Societal Risks, 21 VACCINE 3413, 3415 (2003), http://www.sciencedirect .com/ science/ 
article/ pii/ S0264410X03003967 [https://perma.cc/U3Z8-QNZA].  
155.  Id. 
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reproductive issues are “clouded by an emotional stigma” that can 
lead to partisan positions and produce distracting non-objective 
opinions that misinform the public.156 
Indeed, there is not even consensus around standard 
definitions for assessing outcomes even if background rates of 
malformation and spontaneous abortion might be more 
effectively ascertained.157 
For example, a review commissioned by the World Health 
Organization highlighted the lack of standard definitions of 
outcomes, and standards for measurement of these 
outcomes, relevant to evaluation of vaccines in 
pregnancy.  This lack of standardization poses a challenge 
for conduct of clinical trials, generalizability of safety data, 
and merging of large safety data sets.  This last point is 
critical because large multilocation data sets could optimize 
the evaluation of rare but clinically important outcomes, 
such as microcephaly.158  
Standard definitions are needed for measuring outcomes when 
evaluating vaccine safety studies in pregnant women.159 
C. The Physician-Patient Relationship and the Effect 
on Maternal and Infant Care 
1. Doctor-Patient Communication
While the most immediate effect of these knowledge gaps is 
the lack of data on safety and efficacy for drugs and vaccines that 
may support maternal and infant health, another area affected is 
the communication between physicians and patients.  There is 
good evidence showing that pregnant women refuse 
immunizations based on information in package inserts which 
ranges from statements about there being no information to 
“safety and effectiveness of [X vaccine] have not been established 
156.  Id. at 3414-15. 
157.  See generally id.; T. Roice Fulton et al., A Systematic Review of Adverse Events 
Following Immunization During Pregnancy and the Newborn Period, 33 VACCINE 6453 
(2015).  
158.  Omer & Beigi, supra note 130, at 1228.  
159.  See generally Fulton et al., supra note 157. 
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in pregnant women . . . .”160  The inability of physicians and 
public health authorities to connect statements regarding maternal 
health with product information deters important interventions 
that may help both pregnant women and their unborn children.161 
Healthcare providers are well-positioned to explain the 
benefits of immunizations against vaccine-preventable diseases 
to pregnant women; they have proven their capacity to do so 
through their heavy involvement in administrating the H1N1 
vaccine to pregnant women during the 2009 pandemic.162  
However, research suggests that, broadly speaking, barriers 
remain high between providers and vaccinations because of the 
fear of adverse pregnancy outcomes and lack of awareness of 
national recommendations and product safety information.163 
A 2008 study “analyzed patient and physician knowledge 
regarding the influenza vaccine in pregnancy and examined the 
impact of several interventions to increase immunization 
rates.”164 Approximately 86% of physicians “stated that they 
always recommended vaccinations to their patients” during 
prenatal care.165 When the approximately 14% of physicians who 
did not recommend vaccinations were asked via questionnaire 
about vaccinations during pregnancy, “25% of physicians said 
that there [was] not enough data concerning influenza-related 
complications during pregnancy and concerning vaccine 
efficacy.”166  They were also worried about vaccination side 
effects and the legal risks of vaccinating pregnant women.167  
However, the most frequent answer was that physicians 
understood their patients did not want to be vaccinated 
(42.8%).168 
160.  Shannon Mulvihill, TDaP Vaccine During Pregnancy? A Difficult Decision for 
Any Mom., FOCUS FOR HEALTH, https://www.focusforhealth.org/tdap-vaccine-during-
pregnancy-a-difficult-decision-for-any-mom/ [https://perma.cc/YU64-SZ55]. 
161.  See generally Birte Bödeker et al., Skewed Risk Perceptions in Pregnant Women: 
The Case of Influenza Vaccination, 15 BMC PUB. HEALTH no. 1308 (2015); Britta Panda et 
al., Influenza Vaccination During Pregnancy and Factors for Lacking Compliance with 
Current CDC Guidelines, 24 J. MATERNAL-FETAL & NEONATAL MED. 402 (2011). 
162.  Swamy & Heine, supra note 54, at 213. 
163.  Id. at 222. 
164.  See Panda et al., supra note 161, at 403. 
165.  Id.   
166.  Id.   
167.  Id.   
168.  Id. at 405. 
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In the context of influenza, the combination of physician 
ambivalence and patient refusal can be fatal.  While pregnant 
women comprise approximately 1% of the United States 
population, they totaled 5% of the deaths caused by H1N1 in the 
United States in 2009.169  Moreover, influenza vaccines 
administered during pregnancy may impart important benefits to 
newborns as well. A study conducted in Bangladesh suggests that 
an influenza shot during pregnancy lowers the risk of influenza 
both for the woman and for the baby in the first six months of 
life,170 while a more recent study from South Africa found 
vaccination in pregnant HIV-uninfected and HIV-infected 
African women was immunogenic and provided protection 
against confirmed influenza.171 “The vaccination was also 
effective in HIV-unexposed infants up until 24 weeks after 
birth.”172 
2. Product Labeling
A key component of facilitating the communication between 
physician and patient with respect to immunizations is what the 
physician may say about a vaccine when a pregnant woman asks 
about its safety and efficacy profile.173  Because current clinical 
data used for vaccine labeling comes “either from post hoc 
analyses of inadvertent exposures during pre-licensure trials 
designed to exclude pregnant subjects, or from uncontrolled, 
observational postlicensure studies,”174  physicians may say little 
more than what the product insert says along with language 
adapted from ACIP or ACOG recommendations.175 
The new PLLR adopted by the FDA and effective as of June 
2015 is intended to facilitate meaningful communications 
169.  Alicia M. Siston et al., Pandemic 2009 Influenza A (H1N1) Virus Illness Among 
Pregnant Women in the United States, 303 JAMA 1517, 1522-23 (2010). 
170.  See generally K. Zaman et al., Effectiveness of Maternal Influenza Immunizations 
in Mothers and Infants, 359 NEW ENG. J. MED. 1555 (2008), http://www.nejm.org /doi 
/pdf/10.1056/NEJMoa0708630 [http://perma.cc/3L8J-A43Z]. 
171.  Shabir A. Madhi et al., Influenza Vaccination of Pregnant Women and Protection 
of Their Infants, 371 NEW ENG. J. MED. 918, 930 (2014), http://www.nejm. 
org/doi/full/10.1056/NEJMoa1401480#t=article [https://perma.cc/S7AN-XYSP]. 
172.  Id.  
173.  See generally Bödeker et al., supra note 161. 
174.  See Roberts & Gruber, supra note 18, at 967. 
175.  Id. at 966-67. 
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between physicians and pregnant and lactating women in a 
manner that the old letter-risk system made difficult.176  But, as 
pregnant women are excluded from clinical trials, there is little 
manufacturers may do with respect to adapting their current 
approaches to product labeling.177   
Pediatrician Saad Omer and obstetrician Richard Beigi 
recommend that the FDA issue a “mock label” related to 
pregnancy as a guide to help the industry and public health leaders 
effectively phase into the new PLLR system and provide 
obstetrical care providers clear information.178  This mock label 
should provide guidance for inclusion and format of pregnancy-
related information in sections of the drug labeling that are 
specifically relevant to pregnant women.179  Having clarity 
regarding vaccine labeling related to pregnancy “will help ensure 
that clinicians have a higher level of confidence in pregnancy-
related vaccines and could provide a road map for conducting 
research that can inform labeling and hence clinical decisions.”180 
D. Maternal Vaccines: the Future of Healthy Mothers 
and Children 
This Essay has emphasized that pregnant women are, by 
virtue of the structure of medical research norms, effectively 
disadvantaged as a group relative to other populations just as they 
are in disability jurisprudence, employment, and under other legal 
regimes.  This disadvantage adversely affects them as pregnant 
women (as opposed to, for example, their unborn children).  For 
example, while the reasons are not well-understood (due to 
practices detailed above), pregnant women are at much higher 
risk for severe illness and death when infected by certain strains 
of influenza.  The available medical evidence suggests that 
immunization protects them while conferring less relative benefit 
upon a newborn.  So the constraints on research, labeling, and 
physician attitudes are primarily a disadvantage for women. 
176.  Id.; see generally Requirements for Pregnancy and Lactation Labeling, 79 Fed. 
Reg. 72,064 (Dec. 4, 2014) (to be codified at 21 C.F.R. pt. 201). 
177.  See Roberts & Gruber, supra note 18, at 967. 
178.  Omer & Beigi, supra note 130, at 1227. 
179.  Id. at 1227-28. 
180.  Id. at 1228. 
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The system also stymies the development of vaccines that 
represent the future of infant and early childhood health.  It is 
nearly impossible to overstate the contribution that childhood 
immunizations have made to the lives of children over the last 
century: 
Diseases that used to be common in [the U.S.] and around 
the world, including polio, measles, diphtheria, pertussis 
(whooping cough), rubella (German measles), mumps, 
tetanus, rotavirus and Haemophilus influenzae type b (Hib) 
can now be prevented by vaccination. Thanks to a vaccine, 
one of the most terrible diseases in history—smallpox—no 
longer exists outside the laboratory. Over the years vaccines 
have prevented countless cases of disease and saved millions 
of lives.181 
Programs aimed at expanding access to vaccines—
especially childhood immunizations—have enjoyed enormous 
global financial support from governments, charities, and 
international organizations like UNICEF and the World Health 
Organization.  “Worldwide, more than 30 vaccine doses are 
delivered every second through routine immunization programs. 
This number  has increased dramatically as more vaccines are 
developed . . . and the global community acknowledges that 
vaccines, as a fundamental medical intervention, positively affect 
more lives than any other.”182  In 2013, 6.3 million children under 
five died, compared with 12.7 million in 1990.  Between 1990 
and 2013, under-five mortality declined by 49%, from an 
estimated rate of 90 deaths per 1000 live births to 46.  “The global 
rate of decline has also accelerated in recent years—from 1.2% 
per annum during 1990-1995 to 4.0% during 2005-2013.”183  In 
other words, the world is nearing universal coverage of children 
for known early-childhood immunizations. 
Improving the current system for development and licensure 
of maternal immunizations is critical not only for public health 
emergencies like Zika but also for the next generation of 
181.  Why Are Childhood Vaccines So Important?, CTRS. FOR DISEASE CONTROL & 
PREVENTION (Aug. 18, 2017), http://www.cdc.gov/vaccines/vac-gen/ howvpd.htm 
[https://perma.cc/56QQ-YZKA].  
182.   Berkley, supra note 20, at 179.  
183.  Millennium Development Goals (MDGs), WORLD HEALTH ORG. (May 2015), 
http://www.who.int/mediacentre/factsheets/fs290/en/ [https://perma.cc/2R5Y-5C5G].  
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preventative health measures that are likely to make major gains 
in children’s health.  The first twenty-eight days of life (the 
newborn period), are a child’s most vulnerable.184  In fact, 
newborns account for nearly half of all child deaths before five 
years of age—about 2.9 million deaths each year.185  Although 
additional childhood and adolescent vaccines are being 
developed, immunizations for pregnant women represent a next 
step, supported by a great deal of preliminary evidence, in the 
effort to ensure that mothers remain healthy during pregnancy and 
children are born with as great a chance as possible to lead healthy 
lives.  Vaccination of women during pregnancy is considered the 
most plausible strategy to provide direct antibody protection 
against respiratory syncytial virus (RSV), an infection that kills 
tens of thousands of infants worldwide annually.186  The main 
limitations on the production of a Group B streptococcus 
vaccine—a leading cause of severe invasive disease in young 
infants—are not technical or scientific, but regulatory and legal 
because they involve a vaccine delivered during pregnancy.187  
Many other promising maternal vaccines that may improve infant 
health remain stalled at the conceptual stage.188 
184.  Advancing Maternal Immunization, PATH, http://sites.path.org/cvia/ advancing-
maternal-immunization/ [https://perma.cc/XVZ2-TCKX]. 
185.  Id. 
186.  Helen Y. Chu & Janet A. Englund, Maternal Immunization, 59 CLINICAL 
INFECTIOUS DISEASES 560, 565 (2014), https://www.ncbi.nlm.nih.gov/pmc/articles/ 
PMC4168293/ [https://perma.cc/JF2G-N457]; Harish Nair et al., Global Burden of Acute 
Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children: A 
Systematic Review and Meta-Analysis, 375 LANCET 1545, 1545 (2010), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864404/ [https://perma.cc/E7FH-7N FR]. 
187.  Clare L. Cutland et al., Increased Risk for Group B Streptococcus Sepsis in Young 
Infants Exposed to HIV, Soweto, South Africa, 2004-2008, 21 EMERGING INFECTIOUS 
DISEASES 638, 638 (2015) (“We estimate that use of trivalent GBS vaccine (serotypes Ia, Ib, 
and III) could prevent 2,105 invasive GBS cases and 278 deaths annually among infants in 
South Africa; therefore, vaccination of all pregnant women in this country should be 
explored.”), https:// wwwnc.cdc.gov /eid /article/ 21/ 4/ 14-1562_article [https://perma.cc/ 
X265-3DWW]; Paul T. Heath & Robert G. Feldman, Vaccination Against Group B 
Streptococcus, 4 EXPERT REV. VACCINES 207, 207 (2005), https:// www.ncbi.nlm.nih.gov 
/pubmed /15889994 [https:// perma.cc/9JGV-X9ZQ ] (“The main limitations on the 
production of a Group B streptococcus vaccine are not technical or scientific, but regulatory 
and legal.”).  
188.  See CLINICAL DEVELOPMENT, supra note 58, at 3 (“Scientific advances and 
increasing recognition of unmet potential have led to a recent surge in activity and interest 
in maternal immunization.”); Richard Beigi et al., Maternal Immunization: Opportunities for 
Scientific Advancement, 59 CLINICAL INFECTIOUS DISEASES S408, S412 (2014), 
https://www.ncbi.nlm.nih.gov/pubmed/25425719 [https://perma.cc/W8AP-GVFV].
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V.  CONCLUSION 
Legal scholars are undertaking a crucial and comprehensive 
review of laws aimed at protecting pregnant women from 
discrimination, arguing for improvement of laws in place to 
support the multiple factors that affect healthy pregnancies, and 
urging a more comprehensive view of pregnancy to inform law-
making generally.  This Essay has suggested that there is as great 
or greater a need to apply these critiques to the process that leads 
to lifesaving vaccines for pregnant women, improves meaningful 
communication between pregnant women and their healthcare 
providers, and opens the window to the next advances in 
individual and public health that will secure healthy lives for 
children.  Vaccine-preventable diseases associated with adverse 
maternal, fetal, or infant health may be prevented by 
immunization during pregnancy.  As immunizations like MMR, 
Tdap, and polio reach the world’s poorest children and coverage 
rates in developed countries move higher, the next generation of 
immunizations will be those for which administration during 
pregnancy imparts health benefits to both mothers and children 
that are not realizable either before or after pregnancy. 
